Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

CONCLUSIONS: These analyses support the approved SG dosing regimen of 10 mg/kg as intravenous infusion on days 1 and 8 of 21-day cycles and did not identify a need for dose adjustment based on evaluated covariates or disease characteristics.PMID:38578394 | DOI:10.1007/s40262-024-01366-3

Source: Clinical Breast Cancer - April 5, 2024 Category: Cancer & Oncology Authors: Abhishek G Sathe Indrajeet Singh Pratap Singh Paul M Diderichsen Xiaohui Wang Peter Chang Atiya Taqui See Phan Sandhya Girish Ahmed A Othman Source Type: research